Alejandro Gonzalez-Serna1, Keith Chan2, Benita Yip2, William Chau2, Rachel McGovern2, Hasina Samji2, Viviane Dias Lima3, Robert S Hogg4, Richard Harrigan3. 1. BC Centre for Excellence on HIV/AIDS, Vancouver V6Z1Y6, BC, Canada aglez-serna@cfenet.ubc.ca. 2. BC Centre for Excellence on HIV/AIDS, Vancouver V6Z1Y6, BC, Canada. 3. BC Centre for Excellence on HIV/AIDS, Vancouver V6Z1Y6, BC, Canada Division of AIDS, Department of Medicine, University of British Columbia, Vancouver V6T1Z4, BC, Canada. 4. BC Centre for Excellence on HIV/AIDS, Vancouver V6Z1Y6, BC, Canada Faculty of Health Sciences, Simon Fraser University, Burnaby V5A1S6 BC, Canada.
Abstract
OBJECTIVES: The aim of this study was to describe the rates and predictors of discontinuing first-line antiretroviral therapy in the different eras of treatment over a nearly 20 year period initiated in British Columbia between 1992 and 2010. METHODS: All naive adults who started antiretroviral therapy (first-line antiretroviral therapy) at any hospital or clinic in British Columbia (Canada) in 1992-2010 were included in this population-based retrospective cohort study. We were primarily interested in whether the era of treatment (1992-95, 1996-2000, 2001-05 and 2006-10) was associated with discontinuation (stopping or switching of initial treatment) within 3 years of starting therapy. Weibull survival analysis was used to model the era of treatment and its association with time to discontinuation. RESULTS: The study included 7901 patients. Overall, the probability of discontinuing at 12, 24 and 36 months of treatment was 52%, 68% and 76%, respectively. In the adjusted model, variables associated with discontinuing were earlier treatment era, younger age, low adherence and lower baseline CD4 count. Regarding the 2006-10 period, the probability of discontinuing at 12, 24 and 36 months was 36%, 47% and 53%, respectively. In the adjusted model, the variables associated with discontinuation were younger age, female gender, AIDS-defining illnesses at baseline, low adherence and a protease inhibitor (PI)-based regimen. CONCLUSIONS: Discontinuation rates of first-line therapy have decreased over time, but are still quite high even for the latest drug combinations. In the most recent era, younger women on a PI regimen and those not achieving optimal adherence had the highest risk of discontinuing first-line antiretroviral therapy.
OBJECTIVES: The aim of this study was to describe the rates and predictors of discontinuing first-line antiretroviral therapy in the different eras of treatment over a nearly 20 year period initiated in British Columbia between 1992 and 2010. METHODS: All naive adults who started antiretroviral therapy (first-line antiretroviral therapy) at any hospital or clinic in British Columbia (Canada) in 1992-2010 were included in this population-based retrospective cohort study. We were primarily interested in whether the era of treatment (1992-95, 1996-2000, 2001-05 and 2006-10) was associated with discontinuation (stopping or switching of initial treatment) within 3 years of starting therapy. Weibull survival analysis was used to model the era of treatment and its association with time to discontinuation. RESULTS: The study included 7901 patients. Overall, the probability of discontinuing at 12, 24 and 36 months of treatment was 52%, 68% and 76%, respectively. In the adjusted model, variables associated with discontinuing were earlier treatment era, younger age, low adherence and lower baseline CD4 count. Regarding the 2006-10 period, the probability of discontinuing at 12, 24 and 36 months was 36%, 47% and 53%, respectively. In the adjusted model, the variables associated with discontinuation were younger age, female gender, AIDS-defining illnesses at baseline, low adherence and a protease inhibitor (PI)-based regimen. CONCLUSIONS: Discontinuation rates of first-line therapy have decreased over time, but are still quite high even for the latest drug combinations. In the most recent era, younger women on a PI regimen and those not achieving optimal adherence had the highest risk of discontinuing first-line antiretroviral therapy.
Authors: Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg Journal: Curr HIV/AIDS Rep Date: 2011-12 Impact factor: 5.071
Authors: Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: Kelly A Gebo; John A Fleishman; Richard Conviser; Erin D Reilly; P Todd Korthuis; Richard D Moore; James Hellinger; Philip Keiser; Haya R Rubin; Lawrence Crane; Fred J Hellinger; W Christopher Mathews Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: E N van Roon; J M Verzijl; J R Juttmann; A W Lenderink; M J Blans; A C Egberts Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1999-03-01
Authors: Keri N Althoff; Amy C Justice; Stephen J Gange; Steven G Deeks; Michael S Saag; Michael J Silverberg; M John Gill; Bryan Lau; Sonia Napravnik; Ellen Tedaldi; Marina B Klein; Kelly A Gebo Journal: AIDS Date: 2010-10-23 Impact factor: 4.177
Authors: Katrina C Duncan; Charlotte Reading; Alexandra M Borwein; Melanie C M Murray; Alexis Palmer; Warren Michelow; Hasina Samji; Viviane D Lima; Julio S G Montaner; Robert S Hogg Journal: AIDS Behav Date: 2011-01
Authors: Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Rosario Martinez-Vega; Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Kinh Van Nguyen; Tuti P Merati; Thi Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Oon Tek Ng Journal: Antivir Ther Date: 2018
Authors: Sarah Kok; Alexander R Rutherford; Reka Gustafson; Rolando Barrios; Julio S G Montaner; Krisztina Vasarhelyi Journal: Health Care Manag Sci Date: 2015-01-17
Authors: Julius Y Fonsah; Alfred K Njamnshi; Charles Kouanfack; Fang Qiu; Dora M Njamnshi; Claude T Tagny; Emilienne Nchindap; Léopoldine Kenmogne; Dora Mbanya; Robert Heaton; Georgette D Kanmogne Journal: PLoS One Date: 2017-01-31 Impact factor: 3.240
Authors: Joseph M Lewis; Colette Smith; Adele Torkington; Craig Davies; Shazaad Ahmad; Andrew Tomkins; Jonathan Shaw; Margaret Kingston; Ghadeer Muqbill; Philip Hay; Larissa Mulka; Deborah Williams; Laura Waters; Nataliya Brima; Neal Marshall; Margaret Johnson; Mas Chaponda; Mark Nelson Journal: J Infect Date: 2017-01-29 Impact factor: 6.072
Authors: A Gonzalez-Serna; S Ferrando-Martinez; L Tarancon-Diez; R S De Pablo-Bernal; B Dominguez-Molina; J L Jiménez; M Á Muñoz-Fernández; M Leal; E Ruiz-Mateos Journal: J Transl Med Date: 2017-12-20 Impact factor: 5.531